logo-loader
viewRedx Pharma Plc

Redx Pharma confirms restart of clinical trial for lead cancer drug in H1 2019

Lisa Anson, chief executive of Redx Pharma Plc (LON:REDX), caught up with Proactive's Andrew Scott to discuss the restart of a Phase I/IIa clinical trial of its lead cancer drug in the first half of next year.

The announcement follows what's been described as a “positive” meeting with the Medicines and Healthcare products Regulatory Agency, the drugs watchdog.

Anson says as well as a newly-proposed lower starting dose of RXC004, there will be a revised study protocol, including enhanced safety monitoring.

Quick facts: Redx Pharma Plc

Price: 7 GBX

AIM:REDX
Market: AIM
Market Cap: £8.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Redx Pharma's chief scientific officer talks grant funding for its fibrosis...

Redx Pharma PLC's (LON:REDX) chief scientific officer Dr Richard Armer speaks to Proactive London's Andrew Scott after announcing they'd won grant funding for their latest project. They're collaborating with the Medicines Discovery Catapult, a government body that helps accelerate the...

3 weeks, 5 days ago

2 min read